Common Polymorphisms in&lt;i&gt; GSTA1&lt;/i&gt;, &lt;i&gt;GSTM1&lt;/i&gt; and &lt;i&gt;GSTT1 &lt;/i&gt;Are Associated with Susceptibility to Urinary Bladder Cancer in Individuals from Balkan Endemic Nephropathy Areas of Serbia

Matić, Marija; Dragićević, B; Pekmezović, Tatjana; Šuvakov, Sonja; Savić-Radojević, Ana; Plješa-Ercegovac, Marija; Dragičević, Dejan; Smiljic, Jelena; Simić, Tatjana

doi:10.1620/tjem.240.25

Cited by 7 publications

(13 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Characteristics of the included studies reporting risk or oncologic outcomes of AA-UTC Tables 1 and 2 summarize the characteristics of the 25 studies reporting risk or oncologic outcomes of AA-UTC. [66][67][68] Twenty-four were peer-reviewed articles published from 1991 to 2020, [35][36][37][38][39][40][41][42][44][45][46][47][48][49][50][51][52][53][54][55][56][66][67][68] and one was a master's thesis completed in 2011. 43 Among them, 18 were cohort studies 37,38,[40][41][42][43][44]46,[48][49][50][51][52][53][54][55]56,68 and seven were case-control studies.…”

Section: Comparison Of the Included Studies Between The Present And Previous Systematic Reviewsmentioning

confidence: 99%

“…37,38,41,42,44,51,66 The outcome of interest in 15 studies was risk of primary UTC, including UC, [35][36][37][38][39][40][41][42][43][44][45][46]66 RCC, 37,41,43,67 and BC. 47 In RTRs, post-transplant malignancies were reported. Ten [48][49][50][51][52][53][54][55][56]68 studies reported oncological outcomes of primary AA-UC after surgery; nine [48][49][50][51][52][53][54]56,68 of them reported recurrence, and five 50,[54][55][56]68 of them reported survival outcomes.…”

Section: Comparison Of the Included Studies Between The Present And Previous Systematic Reviewsmentioning

confidence: 99%

“…44 Fourteen studies assessed AA exposure according to the prescription history of AA-containing herbal medicines, 39,46,67 medical records, 38,41,48,53,55,66 results of the questionnaire survey, 45 self-reported data from patients 54 or residence in BEN areas. 35,47,50 By contrast, in addition to AA exposure history, eight studies assessed AA exposure based on the diagnosis of AAN 36,40,[42][43][44]51,56 / BEN. 37 Three molecular epidemiological studies assessed AA exposure based on the detection of AL-DAN adducts and TP53 gene A:T-to-T:A mutations, 49,52 or the genome-wide present AA signature.…”

Section: Comparison Of the Included Studies Between The Present And Previous Systematic Reviewsmentioning

confidence: 99%

See 2 more Smart Citations

Aristolochic acid-associated urinary tract cancers: an updated meta-analysis of risk and oncologic outcomes after surgery and systematic review of molecular alterations observed in human studies

Kang

Chen

Lin

et al. 2021

Therapeutic Advances in Drug Safety

View full text Add to dashboard Cite

Background: The risk of primary aristolochic acid (AA)-associated urothelial carcinoma (AA-UC) has been summarized by a 2013-published meta-analysis. Given that additional evidence has been continuously reported by original studies, an updated meta-analysis is needed. Meanwhile, to complete the whole picture, a systematic review of molecular alterations observed in AA-urinary tract cancers (AA-UTC) was also performed. Methods: We searched PubMed, Embase and four Chinese databases up to October 2020. Observational studies comparing risk or oncologic outcomes of UTC between patients with and without AA exposure were eligible for systematic review and meta-analysis. Studies investigating molecular alterations in AA-UTC using human tissue samples were eligible for systematic review. Results: In total, 38 and 20 studies were included in the systematic review and meta-analysis, respectively. Exposure to AA led to an overall increased risks of primary UTC [UC and renal cell carcinoma (RCC)] (OR 6.085, 95% CI 3.045–12.160) and postoperatively recurrent UC (RR 1.831, 95% CI 1.528–2.194). Subgroup analysis of postoperative primary AA-upper tract UC (AA-UTUC) showed increased risks of bladder recurrence (adjusted RR 1.949, 95% CI 1.462–2.597) and contralateral UTUC recurrence (crude RR 3.760, 95% CI 2.225–6.353), worse overall survival (adjusted HR 2.025, 95% CI 1.432–2.865) and worse disease-specific survival (adjusted HR 3.061, 95% CI 1.190–7.872), but no effect on cancer-specific survival (adjusted HR 0.772, 95% CI 0.269–2.215). High mutation load with AA mutational signature presenting largely in the putative driver genes was observed in AA-UTUC. In contrast, AA mutational signature is rarely found in the mutated RCC driver genes and the mutation load in AA-RCC is low. Therefore, AA has different roles in the genesis of UTUC and RCC. Conclusions: Implementing effective strategies to completely protect people from exposure to AA is urgently needed. Additionally, more effort should be made in identifying the precise carcinogenic mechanisms of AA to determine the future treatment strategies. Plain language summary Risk, recurrence and survival outcomes after surgery and molecular changes possibly involved in the genesis of aristolochic acid-associated urinary tract cancers Background: The association between aristolochic acid (AA) and primary urothelial carcinoma (UC) has been summarized by a 2013-published meta-analysis. Given that additional evidence has been reported in the past 7 years, an updated meta-analysis is needed. Meanwhile, to complete the whole picture, a systematic review of molecular changes possibly involved in AA-mediated urinary tract carcinogenesis was also performed. Methods: We searched PubMed, Embase and four Chinese databases for human studies up to October 2020. Studies comparing the risk of urinary tract cancer (UTC) between patients with and without AA exposure and studies investigating the molecular changes in AA-associated UTC (AA-UTC) using human tissue samples were eligible for inclusion. Thirty-eight studies were finally included. Results: The results showed that exposure to AA was associated with a 6-fold increased risk of primary UTC (UC and renal cell carcinoma, RCC) and a 1.8-fold increased risk of postoperatively recurrent UC. After studies reporting primary AA-upper tract UC (AA-UTUC) were analyzed, a 1.9-fold increased risk of bladder recurrence and a 3.8-fold increased risk of contralateral UTUC recurrence was observed. Additionally, exposure to AA worsened the postoperative survival of patients with UTUC by a 2-fold increased risk of overall death and a 3-fold increased risk of death from other diseases and recurrences. However, there was no effect on death due to cancer. Lastly, AA seemed to play different roles in the etiology of UTUC and RCC based on the observations of different mutation loads and different distributions of AA-induced mutations in AA-UTUC and AA-RCC samples. Conclusions: Implementing effective strategies to completely protect people from exposure to AA is urgently needed. Moreover, more effort should be made in identifying the precise carcinogenic mechanisms of AA-UTC to determine the future treatment strategies.

show abstract

Section: Comparison Of the Included Studies Between The Present And Previous Systematic Reviewsmentioning

confidence: 99%

Section: Comparison Of the Included Studies Between The Present And Previous Systematic Reviewsmentioning

confidence: 99%

Section: Comparison Of the Included Studies Between The Present And Previous Systematic Reviewsmentioning

confidence: 99%

See 1 more Smart Citation

Aristolochic acid-associated urinary tract cancers: an updated meta-analysis of risk and oncologic outcomes after surgery and systematic review of molecular alterations observed in human studies

Kang

Chen

Lin

et al. 2021

Therapeutic Advances in Drug Safety

View full text Add to dashboard Cite

show abstract

“…The control cases were randomly selected from among participants. The genotypes GSTM1-null and GSTT1-null, produced no GSTM1 and GSTT1 protein and consequently completely lack GSTM1 and GSTT1 enzymatic activity (Matic et. al., 2016).…”

Section: Gstm1 and Gstt1 Genotypingmentioning

confidence: 99%

“…al., 2013;Yajie et. al., 2016;Matic et. al., 2016) which include GSTM1 and GSTT1 class deletion polymorphism (GSTM1-null and GSTT1-null).…”

Section: Other Analyses Of S Haematobium Infection Inmentioning

confidence: 99%

IL4, IL13, GSTM1 and T1 variants and susceptibility to Schistosomiasis and associated bladder pathologies in Eggua, Nigeria

Onile¹,

Awobode²,

Agunloye³

et al. 2020

Nig. J. Biotechnol

View full text Add to dashboard Cite

Failure of the human host to elicit adequate immune responses to the adult Schistosoma haematobium worm and continuous strong inflammatory responses to the eggs have been the main causes of bladder pathology in chronic Schistosomiasis. Identification of susceptibility biomarkers for schistosomiasis- associated bladder pathology is necessary in order to detect genetic factors responsible for the infection and spread of the disease. The aim of this study was to identify candidate-biomarkers for susceptibility to schistosomiasis and its associated pathologies. A total of 371 adult participants, comprising 130 males and 241 females from Eggua community, Ogun State, Nigeria, were randomly recruited into a cross sectional study from August 2012 to May 2014. They were screened for S. haematobium ova and bladder pathologies by microscopy and ultrasonography, respectively. Human host susceptibility to schistosomiasis and its associated bladder pathologies were determined by PCR genotyping of Interleukin (IL4 and IL13) genes, and glutathione-S-transferase (GSTT1 and GSTM1) genes. The overall prevalence of S. haematobium in the population was 29.3% (108/369). Bladder pathologies were observed in 32.3% (117/362) of the population. Polymorphisms in IL 4-590 and IL 13-1055 were observed in 24.1% and 9.3% schistosomiasis cases, respectively. The IL 13-1055 polymorphism did not indicate susceptibility to schistosomiasis in males (OR 0.7, 95% CI 0.3-2.1) but a slight risk was found in females (OR 1.1, 95% CI 0.7-1.7). Participants with GSTM1 and GSTT1 polymorphisms expressed elevated risks of bladder pathologies (OR = 4.3, 95% CI 2.0 - 9.2 and OR = 4.2, 95% CI 1.5 – 12.0, respectively), with the pathology and schistosomiasis group having more GST polymorphisms than bladder pathologies. Keywords: Polymorphisms, Cytokines, GST, schistosomiasis and pathologies

show abstract

Glutathione S-Transferase Pi 1 (GSTP1) Gene 313 A/G (rs1695) polymorphism is associated with the risk of urinary bladder cancer: Evidence from a systematic review and meta-analysis based on 34 case-control studies

Song

Chen

Liu

et al. 2019

Gene

View full text Add to dashboard Cite

Common Polymorphisms in<i> GSTA1</i>, <i>GSTM1</i> and <i>GSTT1 </i>Are Associated with Susceptibility to Urinary Bladder Cancer in Individuals from Balkan Endemic Nephropathy Areas of Serbia

Cited by 7 publications

References 24 publications

Aristolochic acid-associated urinary tract cancers: an updated meta-analysis of risk and oncologic outcomes after surgery and systematic review of molecular alterations observed in human studies

Aristolochic acid-associated urinary tract cancers: an updated meta-analysis of risk and oncologic outcomes after surgery and systematic review of molecular alterations observed in human studies

IL4, IL13, GSTM1 and T1 variants and susceptibility to Schistosomiasis and associated bladder pathologies in Eggua, Nigeria

Glutathione S-Transferase Pi 1 (GSTP1) Gene 313 A/G (rs1695) polymorphism is associated with the risk of urinary bladder cancer: Evidence from a systematic review and meta-analysis based on 34 case-control studies

Contact Info

Product

Resources

About